|
Valoración de DCF de GlyCometics, Inc. (GlyC)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
GlycoMimetics, Inc. (GLYC) Bundle
¡Explore las perspectivas financieras de GlyComética, Inc. (Glyc) con nuestra calculadora DCF fácil de usar! Ingrese sus suposiciones con respecto al crecimiento, los márgenes y los gastos para calcular el valor intrínseco de GlyComética, Inc. (GlyC) y mejorar su estrategia de inversión.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | 10.2 | 1.2 | .1 | .0 | .0 | .0 | .0 | .0 | .0 |
Revenue Growth, % | 0 | 0 | -88.59 | -93.54 | -86.65 | -67.2 | -67.2 | -67.2 | -67.2 | -67.2 |
EBITDA | -57.0 | -51.2 | -63.2 | -47.2 | -39.1 | .0 | .0 | .0 | .0 | .0 |
EBITDA, % | 100 | -504.17 | -5446.78 | -62991.23 | -391219.92 | -60 | -60 | -60 | -60 | -60 |
Depreciation | .9 | 1.0 | 1.0 | 1.0 | .2 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 100 | 9.36 | 87.38 | 1377.59 | 1533.01 | 79.35 | 79.35 | 79.35 | 79.35 | 79.35 |
EBIT | -57.9 | -52.2 | -64.2 | -48.2 | -39.3 | .0 | .0 | .0 | .0 | .0 |
EBIT, % | 100 | -513.53 | -5534.16 | -64368.81 | -392752.93 | -60 | -60 | -60 | -60 | -60 |
Total Cash | 158.2 | 137.0 | 90.3 | 47.9 | 41.8 | .0 | .0 | .0 | .0 | .0 |
Total Cash, percent | .0 | .0 | .0 | .1 | .4 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .2 | .0 | .0 | .1 | .2 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 100 | 0.02114533 | 0.11612 | 192.21 | 1758.2 | 60.03 | 60.03 | 60.03 | 60.03 | 60.03 |
Inventories | -4,322.2 | -1,237.1 | -533.8 | -.1 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 100 | -12172.51 | -46017.7 | -192.72 | 0 | -40 | -40 | -40 | -40 | -40 |
Accounts Payable | 1.4 | 2.1 | 2.1 | 1.0 | .9 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 100 | 20.56 | 181.69 | 1294.88 | 8681.15 | 84.11 | 84.11 | 84.11 | 84.11 | 84.11 |
Capital Expenditure | -.1 | -.1 | .0 | -.1 | .0 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | 100 | -0.67408 | -1.29 | -112.37 | -213.94 | -40.39 | -40.39 | -40.39 | -40.39 | -40.39 |
Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITAT | -54.1 | -51.4 | -63.9 | -96.4 | -39.3 | .0 | .0 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | 4,270.1 | -3,134.8 | -766.2 | -630.4 | -39.4 | -.7 | .0 | .0 | .0 | .0 |
WACC, % | 12.68 | 12.7 | 12.7 | 12.7 | 12.7 | 12.7 | 12.7 | 12.7 | 12.7 | 12.7 |
PV UFCF | ||||||||||
SUM PV UFCF | -.6 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | 0 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | -1 | |||||||||
Net Debt | -41 | |||||||||
Equity Value | 40 | |||||||||
Diluted Shares Outstanding, MM | 63 | |||||||||
Equity Value Per Share | 0.64 |
What You Will Get
- Real GlycoMimetics Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on GlycoMimetics’ fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for GlycoMimetics, Inc. (GLYC).
- WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to GLYC.
- Customizable Forecast Assumptions: Adjust growth projections, capital expenditures, and discount rates for accurate modeling.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to GlycoMimetics, Inc. (GLYC).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis.
How It Works
- 1. Access the Template: Download and open the Excel file containing GlycoMimetics, Inc.'s (GLYC) preloaded data.
- 2. Modify Assumptions: Adjust key inputs such as growth rates, WACC, and capital expenditures.
- 3. View Results Instantly: The DCF model automatically calculates intrinsic value and NPV based on your inputs.
- 4. Explore Scenarios: Evaluate multiple forecasts to assess various valuation possibilities.
- 5. Present with Assurance: Deliver professional valuation insights to substantiate your strategic decisions.
Why Choose This Calculator?
- User-Friendly Interface: Perfectly crafted for both novices and seasoned professionals.
- Customizable Inputs: Easily adjust parameters to suit your financial analysis.
- Real-Time Feedback: Observe immediate updates to GlycoMimetics, Inc.'s (GLYC) valuation as you modify inputs.
- Preloaded Data: Comes equipped with GlycoMimetics, Inc.'s (GLYC) latest financial information for swift evaluations.
- Relied Upon by Experts: A go-to tool for investors and analysts seeking to make well-informed choices.
Who Should Use This Product?
- Investors: Accurately assess GlycoMimetics, Inc.'s (GLYC) fair value prior to making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to GlycoMimetics, Inc. (GLYC).
- Consultants: Efficiently customize the template for valuation reports tailored to GlycoMimetics, Inc. (GLYC) clients.
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech companies.
- Educators: Implement it as a teaching resource to illustrate valuation techniques relevant to GlycoMimetics, Inc. (GLYC).
What the Template Contains
- Pre-Filled Data: Contains GlycoMimetics’ historical financials and projections.
- Discounted Cash Flow Model: Editable DCF valuation model featuring automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC using custom inputs.
- Key Financial Ratios: Evaluate GlycoMimetics’ profitability, efficiency, and leverage.
- Customizable Inputs: Easily modify revenue growth, margins, and tax rates.
- Clear Dashboard: Visual representations and tables summarizing essential valuation results.